dasatinib + paclitaxel

Dasatinib + paclitaxel is a combination of two pharmaceutical agents used primarily in oncology research and clinical trials. Dasatinib is an orally available small molecule tyrosine kinase inhibitor that targets BCR-ABL, SRC family kinases (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. It is approved for the treatment of Philadelphia chromosome-positive leukemias such as chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Paclitaxel is a taxoid chemotherapeutic agent that stabilizes microtubules and inhibits their disassembly, thereby blocking cell division. The combination has been investigated in preclinical studies and early-phase clinical trials for synergistic antitumor activity in cancers such as ovarian cancer and pancreatic cancer. Dasatinib may enhance the efficacy of paclitaxel by inhibiting SRC-mediated resistance pathways activated by paclitaxel treatment[1][3][5][6].